In 17,604 obese patients with cardiovascular disease, semaglutide 2.4 mg reduced all-cause death by 19%, non-CV death by 23%, and COVID-19-related death by 34% over 3.3 years compared to placebo.
19% mortality reductionSemaglutide 2.4 mg reduced all-cause death by 19% in obese patients with cardiovascular disease — the first GLP-1 drug to demonstrate a mortality benefit in a large RCT
What the researchers found
Semaglutide 2.4 mg vs placebo reduced all-cause death (HR 0.81, CI 0.71-0.93), non-CV death (HR 0.77, CI 0.62-0.95), and infectious death (HR 0.71, CI 0.51-0.98). Among COVID-19 patients, semaglutide reduced COVID deaths (HR 0.66, CI 0.44-0.96) and serious COVID events (232 vs 277, p=0.04). CV death trended lower (HR 0.85, CI 0.71-1.01).
Why it matters
This is the first major trial to show a GLP-1 peptide drug reduces all-cause mortality in a large population. The unexpected finding of fewer infectious and COVID-19 deaths suggests semaglutide may have anti-inflammatory or immune-modulating effects beyond weight loss and cardiovascular protection.
The numbers in context
17,604 participants randomized. Semaglutide 2.4 mg vs. placebo. Outcomes included all-cause death, CV death, non-CV death, and COVID-19 death.
How the study worked
Pre-specified analysis of the SELECT trial: double-blind RCT randomizing 17,604 participants ≥45 years, BMI ≥27, with established CV disease but without diabetes to semaglutide 2.4 mg weekly or placebo. Mean follow-up 3.3 years. All deaths adjudicated and categorized into CV, non-CV, and specific subcategories including COVID-19.
Who was studied
Overweight/obese adults with cardiovascular disease in the SELECT trial
What this study cannot tell us
COVID-19 analysis is observational within an RCT — semaglutide didn't prevent COVID infection, only reduced severity. The CV death reduction didn't reach statistical significance (p=0.07). Death subcategory analyses have smaller numbers and should be considered exploratory. Trial excluded diabetic patients, limiting generalizability.
How to read the evidence
Rated strong: prespecified analysis of a landmark double-blind RCT with 17,604 participants, adjudicated death endpoints, and published in JACC. Individual death subcategories are exploratory.
When this study was published
Published in 2024. One of the most impactful analyses from the SELECT trial, extending semaglutide's proven benefits from CV events to overall survival.
The bigger picture
This analysis transforms the narrative around semaglutide from a weight loss drug with CV benefits to potentially a life-saving medication with broad mortality reduction. The infectious death reduction raises provocative questions about whether GLP-1 peptides modulate immune function in clinically meaningful ways.
Questions still open
- Does semaglutide directly modulate immune function, or is the infectious death reduction mediated entirely through weight loss and metabolic improvement?
- Would the mortality benefits be similar in diabetic obese patients?
- How long must patients take semaglutide to realize the mortality benefit?
Common questions
Does semaglutide help you live longer?
Does semaglutide protect against COVID-19?
Read the original research
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
Journal of the American College of Cardiology, 84(17), 1632-1642
Citation
Scirica, Benjamin M; Lincoff, A Michael; Lingvay, Ildiko; Bogdanski, Pawel; Buscemi, Silvio; Colhoun, Helen; Craciun, Anca-Elena; Ezhov, Marat; Hardt-Lindberg, Søren; Kleist Jeppesen, Ole; Matos, Ana Laura S A; Node, Koichi; Schiele, Francois; Toplak, Hermann; van Beek, André; Weeke, Peter E; Wiviott, Stephen D; Deanfield, John; Ryan, Donna. (2024). The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.. Journal of the American College of Cardiology, 84(17), 1632-1642. https://doi.org/10.1016/j.jacc.2024.08.007